Berlin, May 15, 2024 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), a leading European cannabis production and distribution company, recorded a significant increase in demand and revenue growth of approximately 160% in April 2024 compared to the same month last year. Revenue growth in the first quarter of 2024 remained below expectations at approx. 26 % compared to the same period of the previous year (revenue in Q1 2024: EUR 6.2 million, revenue in Q1 2023: EUR 4.8 million) due to the uncertain legal situation.

• Revenue in April 2024 increased by around 160% compared to the same month last year
• Significant increase in the number of cannabis patients recorded due to partial legalisation in April 2024
• Continued strong growth expected in financial year 2024

‍

Due to the changes resulting from the “Cannabis Act,” Cantourage assumes that significant growth in revenue can be achieved in 2024 as a whole. The company expects the “Cannabis Act” to provide significant impetus for medical cannabis in 2024, as it is no longer a narcotic. This will lead to simplifications in dispensing by pharmacies and prescriptions by doctors. It is not yet possible to estimate how the trend will develop and how strongly it will affect Cantourage’s revenue and earnings performance. In principle, however, Cantourage expects to benefit greatly from the new legal framework in 2024 as a whole.

‍

The figures relate to an unaudited pro forma consolidation of the operating subsidiaries.‍

‍

Press contact at Cantourage:
‍
Manuel Taverne| taverne@cantourage.com